Negative symptoms—reductions in goal-directed behavior, social motivation, experience of pleasure, speech output and intonation, and emotional expressions—are a key factor underlying the poor functional outcomes observed in schizophrenia (SZ)1. Although promising treatments have been developed2,...
TV-46000 is a long-acting subcutaneous antipsychotic (LASCA) agent that combines risperidone and an innovative, copolymer-based drug delivery technology in a suspension suitable for subcutaneous (sc) administration from a prefilled syringe (PFS) [1, 2]. Other risperidone formulations include R064766...
Auditory verbal hallucinations (AVHs) are reported by 70–80% of patients with schizophrenia1, and approximately 20–40% of these patients demonstrate an unfavorable response to available antipsychotic medications2,3. These medication-resistant AVHs markedly interfere with normal social function...
Schizophrenia is a severe mental disorder with a global prevalence of approximately 1%, characterized by positive symptoms, negative symptoms, and cognitive impairment [1]. This disorder significantly diminishes the quality of life of patients, while imposing substantial disease burdens on families and...
Schizophrenia is a disorder characterized by positive, negative, and cognitive symptoms—that affects about 1% of the population worldwide. Emotional recognition deficit is also a well-known symptom of schizophrenia, which is present at the onset of the mental disorder1 and can highly affect the...